Skip to content
Cefpodoxime
Banan, Vantin (cefpodoxime) is a small molecule pharmaceutical. Cefpodoxime was first approved as Vantin on 1992-08-07. It is used to treat community-acquired infections, cystitis, escherichia coli infections, gonorrhea, and haemophilus infections amongst others in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
stomatognathic diseasesD009057
respiratory tract diseasesD012140
otorhinolaryngologic diseasesD010038
urogenital diseasesD000091642
skin and connective tissue diseasesD017437
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cefpodoxime proxetil
Tradename
Company
Number
Date
Products
VANTINPharmacia & UpjohnN-050674 DISCN1992-08-07
2 products, RLD
VANTINPharmacia & UpjohnN-050675 DISCN1992-08-07
2 products, RLD
BANANSankyoN-050687 DISCN1992-08-07
2 products
BANANSankyoN-050688 DISCN1992-08-07
2 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
cefpodoxime proxetilANDA2023-06-19
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
community-acquired infections—D017714—
cystitisEFO_1000025D003556N30
escherichia coli infectionsEFO_1001318D004927B96.20
gonorrheaDOID_7551D006069A54
haemophilus infectionsEFO_1001127D006192—
klebsiella infectionsEFO_1001353D007710—
maxillary sinusitisEFO_0007361D015523J32.0
otitis mediaEFO_0004992D010033H66.9
pharyngitis—D010612R07.0
proteus infectionsEFO_1001130D011512—
Show 3 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01D: Other beta-lactam antibacterials in atc
— J01DD: Third-generation cephalosporins
— J01DD13: Cefpodoxime
— J01DD64: Cefpodoxime and beta-lactamase inhibitor
HCPCS
No data
Clinical
Clinical Trials
5 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C802————2
DiarrheaD003967HP_0002014R19.71————1
Healthy volunteers/patients—1————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MicrobiotaD064307————11
Urinary tract infectionsD014552EFO_0003103N39.0————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCEFPODOXIME
INNcefpodoxime
Description
Cefpodoxime is a third-generation cephalosporin antibiotic with methoxymethyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamino substituents at positions 3 and 7, respectively, of the cephem skeleton. Given by mouth as its proxetil ester prodrug, it is used to treat acute otitis media, pharyngitis, and sinusitis. It has a role as an antibacterial drug. It is a cephalosporin and a carboxylic acid.
Classification
Small molecule
Drug classcephalosporins
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
COCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\OC)c3csc(N)n3)[C@H]2SC1
Identifiers
PDB—
CAS-ID80210-62-4
RxCUI20489
ChEMBL IDCHEMBL1672
ChEBI ID3504
PubChem CID6335986
DrugBankDB01416
UNII ID7R4F94TVGY (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 3,704 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details